resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression电阻索拉非尼的肾细胞癌是由潜在可逆的基因表达.pdfVIP

Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression 1. 2. 3,4 3 5 Liang Zhang , Manoj Bhasin , Rachel Schor-Bardach , Xiaoen Wang , Michael P. Collins , David 1 6 5,7 3 2 1 Panka , Prabhakar Putheti , Sabina Signoretti , David C. Alsop , Towia Libermann , Michael B. Atkins , James W. Mier1, S. Nahum Goldberg3,4, Rupal S. Bhatt1,8* 1 Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, 2 Division of Interdisciplinary Medicine and Biotechnology, and Genomics and Proteomics Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, 3 Department of Radiology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, 4 Department of Radiology, Hadassah Hebrew University Medical Center, Jerusalem, Israel, 5 Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, United States of America, 6 Departments of Surgery and Medicine, The Transplant Institute at Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, 7 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 8 Kidney Cancer Program of the Dana Farber/Harvard Cancer Center, Boston, Massachusetts, United States of America Abstract Purpose: Resistance to antiangiogenic therapy is an important clinical problem. We examined whether resistance occurs at least in part via